Management of carriers and babies with haemophilia

Summary.  Although up to 30% of babies born with haemophilia do not have a family history of the disorder, the remaining 70% are born in families where haemophilia has been diagnosed. It has been estimated that for each male with haemophilia, there are five potential female carriers. Such women will benefit from knowledge of both their genetic (mutation present or not) and phenotype (level of plasma factor activity) status. Genetic counselling services to provide information and testing, together with plasma factor measurement, should be offered where available to all women at risk of being carriers. It is critical that women know their plasma factor measurement as they may have mild haemophilia (factor 5–30%, reference range 50–150%) which requires management at times of medical and surgical procedures and following trauma. Close liaison between adult and paediatric haemophilia centres and obstetric–gynaecology units is important to ensure that clinical carers identify and address carriers’ needs. Genetic testing should be performed only after a potential carrier has been counselled and supported to receive such information. There is no coercion to accept such testing. An advantage of genetic testing is to then discuss pre‐implantation genetic diagnosis which is an ex‐viro form of prenatal diagnosis. This can assist couples at risk of having a child with haemophilia who wish to reduce their anxieties about reproduction. Approximately 4% of boys with haemophilia, born in countries with good maternal care, will have intracranial haemorrhage in the neonatal period. There are no high‐level evidence‐based guidelines for the management of delivery or of the newborn with haemophilia. Obstetricians or other birth attendants need to be advised of the possibility of delivery of a boy with haemophilia and seek support from a haemophilia specialist during the pregnancy. The mother can then be monitored and plans for delivery be developed between her medical consultants and discussed with her. It is always preferable for a carrier to know of her genetic and phenotypic status before becoming pregnant so that she is informed as to her options and requirements for safe delivery.

[1]  C. Lee,et al.  Pregnancy in carriers of haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  C. Moutou,et al.  ESHRE PGD consortium data collection VII: cycles from January to December 2004 with pregnancy follow-up to October 2005. , 2008, Human reproduction.

[3]  Karina Turdó,et al.  Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. , 2007, Thrombosis research.

[4]  N. Muntjewerff,et al.  ESHRE PGD Consortium data collection V: cycles from January to December 2002 with pregnancy follow-up to October 2003. , 2008, Human reproduction.

[5]  C. Altisent,et al.  A versatile strategy for preimplantation genetic diagnosis of haemophilia A based on F8-gene sequencing. , 2006, Thrombosis and haemostasis.

[6]  S. Pavord,et al.  The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  K. Ponder,et al.  Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: A White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  K. Michaelides,et al.  Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A , 2006, Thrombosis and Haemostasis.

[9]  Peter Braude,et al.  Proof of principle and first cases using preimplantation genetic haplotyping--a paradigm shift for embryo diagnosis. , 2006, Reproductive biomedicine online.

[10]  M. Torchet,et al.  Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  P. Mannucci.  Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. , 2005, Blood.

[12]  M. Robinson,et al.  ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'. , 2005, Human reproduction.

[13]  K. Fijnvandraat,et al.  The impact of unaware carriership on the clinical presentation of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  E. Chalmers.  Haemophilia and the newborn. , 2004, Blood reviews.

[15]  M. Barnes,et al.  Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. , 2004, The Journal of pediatrics.

[16]  A. Munnich,et al.  Single cell co-amplification of polymorphic markers for the indirect preimplantation genetic diagnosis of hemophilia A, X-linked adrenoleukodystrophy, X-linked hydrocephalus and incontinentia pigmenti loci on Xq28 , 2004, Human Genetics.

[17]  G. Koren,et al.  Hemophilia during pregnancy. , 2003, Canadian family physician Medecin de famille canadien.

[18]  K. Blauer,et al.  Microsorttm babies: 1994–2002 preliminary postnatal follow-up results , 2002 .

[19]  A. Veiga,et al.  Preimplantation genetic diagnosis: patients' experiences and attitudes. , 2002, Human reproduction.

[20]  C. Strom,et al.  Polar body-based preimplantation diagnosis for X-linked disorders. , 2002, Reproductive biomedicine online.

[21]  Dena Towner,et al.  Effect of mode of delivery in nulliparous women on neonatal intracranial injury. , 1999, The New England journal of medicine.

[22]  Kulkarni,et al.  Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemophilia Foundation’s Medical and Scientific Advisor , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  S. Viville,et al.  Results of a survey of the legal status and attitudes towards preimplantation genetic diagnosis conducted in 13 different countries , 1998, Prenatal diagnosis.

[24]  K. Keyvanfar,et al.  Births of normal daughters after MicroSort sperm separation and intrauterine insemination, in-vitro fertilization, or intracytoplasmic sperm injection. , 1998, Human reproduction.

[25]  D. Economides,et al.  The obstetric experience of carriers of haemophilia. , 1998, British journal of obstetrics and gynaecology.

[26]  J. Harper,et al.  Obstetric outcome of pregnancies resulting from embryos biopsied for pre‐implantation diagnosis of inherited disease , 1996, British journal of obstetrics and gynaecology.

[27]  R. Ljung,et al.  The impact of prenatal diagnosis on the incidence of haemophilia in Sweden , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  R. Ljung,et al.  Normal vaginal delivery is to be recommended for haemophilia carrier gravidae , 1994, Acta paediatrica.

[29]  M. Mikkelsen.  The impact of prenatal diagnosis on the incidence of Down syndrome in Denmark. , 1992, Birth defects original article series.

[30]  D. Griffin,et al.  Fluorescent in-situ hybridization to interphase nuclei of human preimplantation embryos with X and Y chromosome specific probes. , 1991, Human reproduction.

[31]  A. H. Handyside,et al.  Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification , 1990, Nature.

[32]  J. Delhanty,et al.  BIOPSY OF HUMAN PREIMPLANTATION EMBRYOS AND SEXING BY DNA AMPLIFICATION , 1989, The Lancet.

[33]  S. A. Larsson,et al.  Deaths in Swedish hemophiliacs, 1957-1980. , 2009, Acta medica Scandinavica.